2017
DOI: 10.23893/1307-2080.aps.0552
|View full text |Cite
|
Sign up to set email alerts
|

Biorelevant and quality control dissolution method development and validation of quetiapine fumarate tablets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 7 publications
0
2
0
Order By: Relevance
“…Dissolution is an important test in formulation development studies and is conducted in order to determine a drug's dosage for properties. Dissolution is an official test that is commonly used as a predictor of in vivo performance that is simulated to evaluate the performance of solid dosage forms, transdermal patches, and suspensions, and it is routinely used in quality control (QC) and research and development (R&D) studies [11]. In the case of generic product development (Favipiravir 200 mg Tablets) in the Abdi Ibrahim Research & Development laboratory, these studies need to be performed for a comparison with the reference product (Avigan Tablets 200 mg ® ).…”
Section: Introductionmentioning
confidence: 99%
“…Dissolution is an important test in formulation development studies and is conducted in order to determine a drug's dosage for properties. Dissolution is an official test that is commonly used as a predictor of in vivo performance that is simulated to evaluate the performance of solid dosage forms, transdermal patches, and suspensions, and it is routinely used in quality control (QC) and research and development (R&D) studies [11]. In the case of generic product development (Favipiravir 200 mg Tablets) in the Abdi Ibrahim Research & Development laboratory, these studies need to be performed for a comparison with the reference product (Avigan Tablets 200 mg ® ).…”
Section: Introductionmentioning
confidence: 99%
“…QF is an antipsychotic drug for treating schizophrenia and the chemical structure is shown in Figure . QF is administered twice a day and the problem of patients skipping doses has been reported in most cases . Hence, the need for a delivery system for QF that could offers extended release (ER), minimize side effects due to over‐dosage with improve compliance in schizophrenia patients and in which QF does not have any chemical interactions with the hydrogel matrix.…”
Section: Resultsmentioning
confidence: 99%